Clinical trial · Interventional
Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma
Phase II Study of Low Intensity Allogeneic Transplantation in Mantle Cell Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Giving chemotherapy and monoclonal antibody therapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying donor stem cell transplant in treating patients with mantle cell lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (8)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| alemtuzumab | Biological | Alemtuzumab | ALIAS |
| allogeneic bone marrow transplantation | Procedure | — | UNRESOLVED |
| carmustine | Drug | Carmustine | ALIAS |
| cytarabine | Drug | Cytarabine | ALIAS |
| donor lymphocytes | Biological | — | UNRESOLVED |
| etoposide | Drug | Etoposide | ALIAS |
| melphalan | Drug | Melphalan | ALIAS |
| peripheral blood stem cell transplantation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression-free survival
Secondary outcomes (2)
- measure
- Overall survival
- measure
- Toxicity
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of mantle cell lymphoma * No relapsed or progressive disease * Achieved at least a partial remission following induction chemotherapy * HLA-matched donor available * Blood samples from both patient and donor available for chimerism studies * No central nervous system involvement PATIENT CHARACTERISTICS: * ECOG performance status 2-4 * Considered fit for transplant by treating physician * Serum bilirubin ≤ 1.5 times upper limit of normal * Alkaline phosphatase ≤ 2 times normal * Creatinine clearance ≥ 50 mL/min * Ejection fraction \> 50% (no inadequate cardiac function) * Not pregnant or nursing * Negative pregnancy test * No symptomatic respiratory compromise * No serious concurrent disease which would preclude allograft * No known serological positivity for hepatitis B, hepatitis C, or HIV * No history of a psychological illness or condition that would affect compliance * No previous malignancy within the past 5 years except nonmelanoma skin tumors or stage 0 (in situ) cervical carcinoma PRIOR CONCURRENT THERAPY: * See Disease Characteristics
References
Publications (0)
Data not yet available